SAN CARLOS, Calif.--10/23/25--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056)...
Spherics Secures $26.4M Financing to Advance Clinical Programs Based on Proprietary Oral Drug Delivery Platform
Spherics, Inc., an emerging pharmaceutical company focused on applying its oral drug delivery platform to develop products with improved therapeutic profiles, today announced that it has successfully completed its Series C round of financing, raising $26.4M. The proceeds from this financing will be used to advance the Company’s pipeline of products based on its proprietary drug delivery technologies, as well as enhance its commercialization and business development capabilities.
